Petra Feyer1,2, Marie-Luise Sautter-Bihl3, Wilfried Budach4, Jürgen Dunst5, Wulf Haase6, Wolfgang Harms7, Felix Sedlmayer8, Rainer Souchon9, Frederik Wenz10, Rolf Sauer11. 1. Klinikum Neukölln, Berlin, Germany. petra.feyer@vivantes.de. 2. Klinik für Strahlentherapie, Radioonkologie und Nuklearmedizin, Vivantes Klinikum Neukölln, Rudower Straße 48, 12351, Berlin, Deutschland. petra.feyer@vivantes.de. 3. Municipal Hospital, Karlsruhe, Germany. 4. University Hospital, Düsseldorf, Germany. 5. University Hospital Schleswig-Holstein, Lübeck, Germany. 6. Formerly St. Vincentius Kliniken, Karlsruhe, Germany. 7. St. Clara Hospital, Basel, Switzerland. 8. University Hospital, Landeskrankenhaus Salzburg, Salzburg, Austria. 9. University Hospital Tübingen, Tübingen, Germany. 10. Department of Radiation Oncology, University Medical Center Mannheim, Mannheim, Germany. 11. University Hospital Erlangen, Erlangen, Germany.
Abstract
PURPOSE: To provide recommendations for palliative treatment of brain metastases (BM) and leptomeningeal carcinomatosis (LC) in breast cancer patients with specific emphasis on radiooncologic aspects. METHODS: The breast cancer expert panel of the German Society of Radiation Oncology (DEGRO) performed a comprehensive survey of the literature comprising national and international guidelines, lately published randomized trials, and relevant retrospective analyses. The search included publications between 1995-2008 (PubMed and Guidelines International Network [G-I-N]). Recommendations were devised according to the panel's interpretation of the evidence referring to the criteria of EBM. RESULTS: Aim of any treatment of BM and LC is to alleviate symptoms and improve neurologic deficits. Close interdisciplinary cooperation facilitates rapid diagnosis and onset of therapy, tailored to the individual and clinical situation. Treatment decisions for BM should be based on the allocation to three prognostic groups defined by recursive partitioning analysis (RPA). Karnofsky Performance Score (KPS) is the strongest prognostic parameter. Together with the extent of the disease, KPS determines whether excision or radiosurgery/stereotactic radiotherapy is feasible and if exclusive or additional whole-brain radiotherapy (WBRT) is indicated. With adequate therapy, survival may be up to 3 years. For LC, treatment is mostly indicated for patients with positive cytology or in case of strongly indicative signs and symptoms. Radiotherapy (WBRT and involved-field irradiation of bulky spinal lesions) and chemotherapy (systemically or intrathecally applied methotrexate, thiotepa and cytarabine) are both effective and may prolong survival from several weeks to 4-6 months. CONCLUSION: Radiotherapy is an effective tool for palliative treatment of BM and LC.
PURPOSE: To provide recommendations for palliative treatment of brain metastases (BM) and leptomeningeal carcinomatosis (LC) in breast cancerpatients with specific emphasis on radiooncologic aspects. METHODS: The breast cancer expert panel of the German Society of Radiation Oncology (DEGRO) performed a comprehensive survey of the literature comprising national and international guidelines, lately published randomized trials, and relevant retrospective analyses. The search included publications between 1995-2008 (PubMed and Guidelines International Network [G-I-N]). Recommendations were devised according to the panel's interpretation of the evidence referring to the criteria of EBM. RESULTS: Aim of any treatment of BM and LC is to alleviate symptoms and improve neurologic deficits. Close interdisciplinary cooperation facilitates rapid diagnosis and onset of therapy, tailored to the individual and clinical situation. Treatment decisions for BM should be based on the allocation to three prognostic groups defined by recursive partitioning analysis (RPA). Karnofsky Performance Score (KPS) is the strongest prognostic parameter. Together with the extent of the disease, KPS determines whether excision or radiosurgery/stereotactic radiotherapy is feasible and if exclusive or additional whole-brain radiotherapy (WBRT) is indicated. With adequate therapy, survival may be up to 3 years. For LC, treatment is mostly indicated for patients with positive cytology or in case of strongly indicative signs and symptoms. Radiotherapy (WBRT and involved-field irradiation of bulky spinal lesions) and chemotherapy (systemically or intrathecally applied methotrexate, thiotepa and cytarabine) are both effective and may prolong survival from several weeks to 4-6 months. CONCLUSION: Radiotherapy is an effective tool for palliative treatment of BM and LC.
Authors: W Boogerd; M J van den Bent; P J Koehler; J J Heimans; J J van der Sande; N K Aaronson; A A M Hart; J Benraadt; Ch J Vecht Journal: Eur J Cancer Date: 2004-12 Impact factor: 9.162
Authors: May N Tsao; Nancy S Lloyd; Rebecca K S Wong; Eileen Rakovitch; Edward Chow; Normand Laperriere Journal: Cancer Treat Rev Date: 2005-06 Impact factor: 12.111
Authors: K J Murray; C Scott; H M Greenberg; B Emami; M Seider; N L Vora; C Olson; A Whitton; B Movsas; W Curran Journal: Int J Radiat Oncol Biol Phys Date: 1997-10-01 Impact factor: 7.038
Authors: Ulrich Herrlinger; Heike Förschler; Wilhelm Küker; Richard Meyermann; Michael Bamberg; Johannes Dichgans; Michael Weller Journal: J Neurol Sci Date: 2004-08-30 Impact factor: 3.181
Authors: Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: D Antonadou; M Paraskevaidis; G Sarris; N Coliarakis; I Economou; P Karageorgis; N Throuvalas Journal: J Clin Oncol Date: 2002-09-01 Impact factor: 44.544
Authors: Nancy U Lin; Véronique Diéras; Devchand Paul; Dominique Lossignol; Christos Christodoulou; Hans-Joachim Stemmler; Henri Roché; Minetta C Liu; Richard Greil; Eva Ciruelos; Sibylle Loibl; Stefania Gori; Andrew Wardley; Denise Yardley; Adam Brufsky; Joanne L Blum; Stephen D Rubin; Bernie Dharan; Klaudia Steplewski; Denise Zembryki; Cristina Oliva; Debasish Roychowdhury; Paolo Paoletti; Eric P Winer Journal: Clin Cancer Res Date: 2009-02-15 Impact factor: 12.531
Authors: K Fizazi; B Asselain; A Vincent-Salomon; M Jouve; V Dieras; T Palangie; P Beuzeboc; T Dorval; P Pouillart Journal: Cancer Date: 1996-04-01 Impact factor: 6.860
Authors: Rainer Souchon; Petra Feyer; Christoph Thomssen; Tanja Fehm; Ingo Diel; Ulrike Nitz; Wolfgang Janni; Joachim Bischoff; Rolf Sauer Journal: Breast Care (Basel) Date: 2010-12 Impact factor: 2.860
Authors: Sara Y Brucker; Markus Wallwiener; Rolf Kreienberg; Walter Jonat; Matthias W Beckmann; Michael Bamberg; Diethelm Wallwiener; Rainer Souchon Journal: Strahlenther Onkol Date: 2011-01-21 Impact factor: 3.621
Authors: Nicholas B Figura; Victoria T Rizk; Avan J Armaghani; John A Arrington; Arnold B Etame; Hyo S Han; Brian J Czerniecki; Peter A Forsyth; Kamran A Ahmed Journal: Breast Cancer Res Treat Date: 2019-06-17 Impact factor: 4.872
Authors: Kavita V Dharmarajan; Shayna E Rich; Candice A Johnstone; Lauren M Hertan; Randy Wei; Lauren E Colbert; Joshua A Jones; Arif H Kamal; Christopher A Jones Journal: J Palliat Med Date: 2018-02-12 Impact factor: 2.947